Dr.NateNeph said:The liver data is among the strongest non-weight findings in the class.
I read this differently from Dr.NateNeph, on substance rather than tone. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
Dr.ObesityLA said:Small molecule does not automatically mean cheap.
Coming at Dr.ObesityLA’s question from a different direction. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsA narrower follow-up, since the general answer is now clear:
Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?
OP back with an update, since a thread like this is useless without one.
Coming back a few months on. It held. Nothing dramatic to report, which is the report.